Q-Med has received 29.1 MUSD from Medicis

Due to the fact that the American regulatory authority, the U.S. Food and Drug Administration (FDA), has approved PERLANE for sales in the USA, Q-Med has received 29.1 MUSD from Medicis (197.4 MSEK). The payment is the last additional purchase sum from the agreement that was entered into with Medicis in 2003. The agreement has thereby generated a total purchase sum of 160 MUSD. Furthermore, Q-Med has exclusive manufacturing rights for the North American market for ten years.

In connection with the payment, the previous provision of 34.5 MSEK for research and development costs will be reversed.

The first deliveries of PERLANE will soon be made.